ProQR Therapeutics N.V (NASDAQ: PRQR)’s stock price has gone decline by -9.12 in comparison to its previous close of 3.29, however, the company has experienced a -16.01% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-12-10 that LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform.
Is It Worth Investing in ProQR Therapeutics N.V (NASDAQ: PRQR) Right Now?
The stock has a 36-month beta value of 0.23. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRQR is 74.28M, and at present, short sellers hold a 0.25% of that float. On December 13, 2024, the average trading volume of PRQR was 1.45M shares.
PRQR’s Market Performance
PRQR’s stock has seen a -16.01% decrease for the week, with a -24.49% drop in the past month and a 63.39% gain in the past quarter. The volatility ratio for the week is 6.26%, and the volatility levels for the past 30 days are at 5.83% for ProQR Therapeutics N.V The simple moving average for the past 20 days is -15.60% for PRQR’s stock, with a 29.66% simple moving average for the past 200 days.
Analysts’ Opinion of PRQR
Many brokerage firms have already submitted their reports for PRQR stocks, with Raymond James repeating the rating for PRQR by listing it as a “Strong Buy.” The predicted price for PRQR in the upcoming period, according to Raymond James is $14 based on the research report published on October 29, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see PRQR reach a price target of $2. The rating they have provided for PRQR stocks is “Buy” according to the report published on November 08th, 2023.
JMP Securities gave a rating of “Mkt Outperform” to PRQR, setting the target price at $5 in the report published on March 30th of the previous year.
PRQR Trading at -11.33% from the 50-Day Moving Average
After a stumble in the market that brought PRQR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.28% of loss for the given period.
Volatility was left at 5.83%, however, over the last 30 days, the volatility rate increased by 6.26%, as shares sank -24.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +64.15% upper at present.
During the last 5 trading sessions, PRQR fell by -16.08%, which changed the moving average for the period of 200-days by +48.26% in comparison to the 20-day moving average, which settled at $3.54. In addition, ProQR Therapeutics N.V saw 51.01% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PRQR
Current profitability levels for the company are sitting at:
- -1.67 for the present operating margin
- 0.92 for the gross margin
The net margin for ProQR Therapeutics N.V stands at -1.34. The total capital return value is set at -0.44. Equity return is now at value -67.62, with -19.30 for asset returns.
Based on ProQR Therapeutics N.V (PRQR), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -7.23. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 109.82.
Currently, EBITDA for the company is -24.1 million with net debt to EBITDA at 2.68. When we switch over and look at the enterprise to sales, we see a ratio of 12.79. The receivables turnover for the company is 13.68for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.
Conclusion
To sum up, ProQR Therapeutics N.V (PRQR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
